The Malaysia nuclear medicine market was valued at $33.68 million in 2020, and is projected to reach $70.24 million by 2028, registering a CAGR of 9.86% from 2021 to 2028.
Radiopharmaceuticals are pharmaceutical formulations comprise radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance used in the treatment of cancer and cardiac & neurological disorders. Moreover, nuclear medicines of modality, SPECT and PET work as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Applications such as lymphoma and bone metastasis use radiopharmaceuticals, also known as nuclear medicines. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedure. More convenient therapeutic radiopharmaceuticals for oncology and cancer treatment replace the conventional chemotherapy methods to open up new avenues in the radiopharmaceuticals market.
The market is currently in its growth stage driven by increase in the number of cancer cases in the Malaysian country and the surge in awareness about nuclear medicine. Convenience of treatment with minimally invasive techniques attracts more patients toward the radiopharmaceuticals mode of treatment as compared to chemotherapy. The factors that drive the radiopharmaceuticals industry include increase in incidence of cardiac patients and adoption of clear imaging techniques such as SPECT and PET in Malaysia, with the help of diagnostic equipment.
The factors that hinder the growth of the market include supply shortages, logistical difficulties, stringent regulations related to the use of nuclear medicine and limited number of trained medical personnel.
The Malaysia nuclear medicine market is segmented into type, modality, application and end user. On the basis of type the market is divided into diagnostics, therapeutics, and biochemistry research. Based on modality the market is segmented into, SPECT, PET, beta emitters, alpha emitters, brachytherapy and others. Furthermore, SPECT is divided into Technetium 99m, Chromium-51, Gallium-67 and others. In addition PET is further divided into Fluorine 18, Gallium-68, and others. On the basis of application, the market is segmented into oncology, cardiology, thyroid, neurology and others. Based on end user, market is categorized into hospitals & diagnostic centers and research institutes
The market is currently in its growth stage driven by increase in the number of cancer cases in the Malaysian country and the surge in awareness about nuclear medicine. Convenience of treatment with minimally invasive techniques attracts more patients toward the radiopharmaceuticals mode of treatment as compared to chemotherapy. The factors that drive the radiopharmaceuticals industry include increase in incidence of cardiac patients and adoption of clear imaging techniques such as SPECT and PET in Malaysia, with the help of diagnostic equipment.
The factors that hinder the growth of the market include supply shortages, logistical difficulties, stringent regulations related to the use of nuclear medicine and limited number of trained medical personnel.
The Malaysia nuclear medicine market is segmented into type, modality, application and end user. On the basis of type the market is divided into diagnostics, therapeutics, and biochemistry research. Based on modality the market is segmented into, SPECT, PET, beta emitters, alpha emitters, brachytherapy and others. Furthermore, SPECT is divided into Technetium 99m, Chromium-51, Gallium-67 and others. In addition PET is further divided into Fluorine 18, Gallium-68, and others. On the basis of application, the market is segmented into oncology, cardiology, thyroid, neurology and others. Based on end user, market is categorized into hospitals & diagnostic centers and research institutes
Key benefits for stakeholders
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2020 to 2028, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of factors that drive and restrain the growth of the market is provided.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Type
- Diagnostics
- Therapeutics
- Biochemistry Research
By Modality
- SPECT
- Technetium 99m
- Chromium-51
- Gallium-67
- Others
- PET
- Fluorine 18
- Gallium-68
- Others
- Beta emitters
- Alpha emitters
- Brachytherapy
- Others
By Application
- Oncology
- Cardiology
- Thyroid
- Neurology
- Others
By End User
- Hospitals and Diagnostic Centers
- Research Institutes
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Cardinal Health, Inc.
- Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.)
- GE Healthcare,
- Ion Beam Applications (Ion Beam Applications, SA)
- Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.)
- MERCK KGAA (Sigma Aldrich)
- Novartis AG (Advanced Accelerator Applications S.A.)
- Otsuka Holding Co., Ltd. (ABX advanced biochemical compounds GmbH)
- Siemens Healthcare GmbH
- Taiyo Nippon Sanso Corporation (Mitsubishi Chemical Holdings Corp)
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: MALAYSIA NUCLEAR MEDICINE MARKET, BY TYPE
CHAPTER 5: MALAYSIA NUCLEAR MEDICINE MARKET, BY MODALITY
CHAPTER 6: MALAYSIA NUCLEAR MEDICINE MARKET, BY APPLICATION
CHAPTER 7: MALAYSIA NUCLEAR MEDICINE MARKET, BY END USER
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Fujifilm Holdings Corporation (Irvine Scientific Sales Company Inc.)
- GE Healthcare
- Ion Beam Applications (Ion Beam Applications SA)
- Lantheus Holdings Inc. (Lantheus Medical Imaging Inc.)
- MERCK KGAA (Sigma Aldrich)
- Novartis AG (Advanced Accelerator Applications S.A.)
- Otsuka Holding Co. Ltd. (ABX advanced biochemical compounds GmbH)
- Siemens Healthcare GmbH
- Taiyo Nippon Sanso Corporation (Mitsubishi Chemical Holdings Corp)
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 139 |
| Published | June 2021 |
| Forecast Period | 2020 - 2028 |
| Estimated Market Value ( USD | $ 33.68 million |
| Forecasted Market Value ( USD | $ 70.24 million |
| Compound Annual Growth Rate | 9.6% |
| Regions Covered | Malaysia |
| No. of Companies Mentioned | 9 |
